Across TCGA pan-cancer cohorts, COLCA2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated COLCA2 data layer compared with 27 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher COLCA2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated COLCA2 expression acts as an unfavorable survival marker.
LUAD, MESO, and UCEC are the cancer types where COLCA2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.